Ascletis reports preclinical results for oral and long-acting obesity drugs

Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said ASC30_48 FDC produced approximately 52% greater relative weight reduction than ASC30 alone in cynomolgus monkeys, while ASC37 showed potential for once-monthly to once-quarterly dosing.
- ASC30_48 FDC reduced monkey body weight by 10.5% on Day 9.
- The combination delivered approximately 52% greater relative weight reduction than ASC30 alone.
- ASC37 had a 372-hour half-life in a non-human primate study.
- ASC37 is designed for once-monthly to once-quarterly subcutaneous administration.
- Ascletis plans further clinical evaluation of the programs.
Oral combination produced greater weight loss in monkeys
Ascletis presented the findings at ObesityWeek® 2026, being held November 14 to 17, 2026, in Washington, DC. The data covered ASC48, an oral small molecule GIPR agonist, ASC30_48 FDC, a fixed-dose combination of ASC30 and ASC48, and ASC37, a long-acting GLP-1R/GIPR/GCGR triple peptide agonist.
In a randomized study, 15 male cynomolgus monkeys received once-daily oral doses for eight consecutive days. On Day 9, body weight had decreased by 10.5% in the ASC30_48 FDC group, compared with 6.9% for ASC30 monotherapy and 1.7% for ASC48 monotherapy. According to Ascletis, the combination delivered approximately 52% greater relative body weight reduction than ASC30 alone, with the proportion of weight loss increased by an additional 3.6%.
Ascletis describes ASC30_48 FDC as a potential first-in-class, one-pill, once-daily oral treatment for obesity and other metabolic diseases. The company said the preclinical results support advancing the program into further clinical development.
ASC48 showed selective GIPR activity and oral exposure
In an in vitro human GIPR-mediated cAMP activation assay, ASC48 achieved an EC 50 of 1 pM, compared with 3 pM for tirzepatide. The compound showed no activity against human GLP-1R or human GCGR under the tested conditions, with IC 50 values greater than 10μM, supporting its selective activity for human GIPR.
After eight repeated oral doses of ASC48 at 5 mg/kg in cynomolgus monkeys, the reported half-life was 16.2 hours and the AUC 0, 24h was 14,500 h*ng/mL. Ascletis said these findings demonstrate oral bioavailability and drug exposure in non-human primates, and, together with the efficacy study, support further evaluation of a once-daily oral regimen in humans.
ASC37 supports longer intervals between injections
Ascletis developed ASC37 using its Artificial Intelligence-Assisted Structure-Based Drug Discovery, or AISBDD, and Ultra-Long-Acting Platform, or ULAP, technologies. The triple agonist is designed for subcutaneous administration once monthly to once quarterly, with an injection volume of no more than 1 mL.
In a non-human primate study, ASC37 had an observed half-life of 372 hours, or 15.5 days, after subcutaneous administration at 0.5 mg/kg. Retatrutide, used in an aqueous formulation at the same dose, had a half-life of 57.8 hours, approximately 2.4 days. Ascletis said ASC37's half-life was approximately 6.4 times as long, supporting its potential for longer-interval dosing.
ASC37 also showed an EC 50 of 0.9858 nM in an in vitro insulin secretion assay, compared with 23.03 nM for retatrutide. In diet-induced obese mice, body weight fell by 14.1%, 30.1% and 41.5% at doses of 1, 10 and 30 nmol/kg, respectively, by Day 12, compared with a 4.7% decrease in the vehicle group. Cumulative food intake also decreased in a dose-dependent manner.
Clinical testing will determine the programs' next steps
The results remain preclinical and do not establish how either program will perform in humans. Ascletis said ASC37's pharmacokinetics, safety and efficacy will be evaluated further through clinical trials.
The company says it is developing oral small molecules and peptides that target GLP-1R, GIPR, GCGR and amylin pathways. Its lead program, ASC30, is being evaluated in two global Phase III studies in obesity. The newly presented findings give Ascletis additional support for pursuing both a daily oral combination and a longer-acting injectable approach, but future clinical studies will determine whether the observed animal results translate into human treatment options.

